Comparative Pharmacology
Head-to-head clinical analysis: OXTRIPHYLLINE versus THEOCLEAR L A 260.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXTRIPHYLLINE versus THEOCLEAR L A 260.
OXTRIPHYLLINE vs THEOCLEAR L.A.-260
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.
Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing cAMP levels, and antagonizing adenosine receptors.
200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.
Theophylline (THEOCLEAR L.A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/mL.
None Documented
None Documented
Adults: 3-5 hours (non-smokers); smokers: 4-6 hours; children: 1-4 hours; neonates: 20-30 hours; congestive heart failure or hepatic cirrhosis: prolonged up to 10-20 hours. Note: Oxtriphylline is a choline salt of theophylline, and its half-life reflects theophylline kinetics.
Clinical Note
moderateOxtriphylline + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Acemetacin
"The therapeutic efficacy of Acemetacin can be decreased when used in combination with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Clotrimazole
Terminal elimination half-life is approximately 6-12 hours in adults (range 3-12 hours, prolonged in congestive heart failure, liver disease, and with certain drugs). In neonates, half-life is prolonged (24-36 hours).
Renal: ~70-80% as unchanged drug and metabolites (including theophylline); biliary/fecal: minimal (<10%)
Renal elimination of unchanged drug (10%) and hepatic metabolism (90%). Metabolism is primarily via CYP1A2 and CYP3A4, with metabolites excreted in urine (about 80% of the dose) and feces (about 20%).
Category C
Category C
Bronchodilator
Bronchodilator
"The metabolism of Clotrimazole can be decreased when combined with Oxtriphylline."